-
1.发明授权
公开(公告)号：US5298392A
公开(公告)日：1994-03-29
申请号：US883815
申请日：1992-05-13
CPC分类号： C12Q1/689 , Y10T436/25375
摘要： Processes and kits therefor for detection of water-borne pathogens and indicator organisms in water samples by recovering cells of the pathogens or indicator organisms from a water sample, lysing the cells to recover undegraded DNA, amplifying a target gene sequence of a target gene present in cells of the pathogens or indicator organisms by polymerase chain reaction amplification and detecting the presence of amplified target gene sequence to determine the presence or absence of pathogens or indicator organism in the test sample.
摘要翻译： 用于通过从水样中回收病原体或指示生物的细胞，裂解细胞以回收未降解的DNA，扩增存在于靶标基因中的靶基因的靶基因序列，从而检测水样中水性病原体和指示生物体的方法和试剂盒 通过聚合酶链反应扩增，检测病原体或指示生物的细胞，并检测扩增的靶基因序列的存在，以确定测试样品中病原体或指示生物的存在或不存在。
-
![Substitued tetrahydro-1,3,5-triazin-2[1H]-thiones as anti-atherosclerotic agents](/abs-image/US/2001/07/31/US06268364B1/abs.jpg.150x150.jpg)
2.发明授权Substitued tetrahydro-1,3,5-triazin-2[1H]-thiones as anti-atherosclerotic agents 失效将取代的四氢-1,3,5-三嗪-2 [1H] - 噻二唑作为抗动脉粥样硬化剂公开(公告)号：US06268364B1
公开(公告)日：2001-07-31
申请号：US09483711
申请日：2000-01-14
IPC分类号： A61K3153
CPC分类号： C07D251/08
摘要： This invention provides compounds of formula 1 having the structure wherein R1, R2, R3, R4, and R5 are each independently, hydrogen, halogen, alkyl, cycloalkyl, alkenyl, alkynyl, phenylalkyl, alkoxy, aryloxy, fluoroalkoxy, trifluoromethyl, alkylthio, alkylsulfony, —SCF3, nitro, alkylamino, or dialkylamino; R6 is hydrogen, alkyl, cycloalkyl, or arylalkyl; and R7 is alkyl, cycloalkyl, or arylalkyl or a pharmaceutically acceptable salt thereof which are useful as antiatherosclerotic agents.
摘要翻译： 本发明提供具有其中R 1，R 2，R 3，R 4和R 5各自独立地为氢，卤素，烷基，环烷基，烯基，炔基，苯基烷基，烷氧基，芳氧基，氟烷氧基，三氟甲基，烷硫基，烷基磺酰基， SCF 3，硝基，烷基氨基或二烷基氨基; R 6是氢，烷基，环烷基或芳基烷基; 和R7是可用作抗动脉粥样硬化剂的烷基，环烷基或芳烷基或其药学上可接受的盐。
-
公开(公告)号：US5512479A
公开(公告)日：1996-04-30
申请号：US136792
申请日：1993-10-14
申请人： Robert J. Steffan
发明人： Robert J. Steffan
CPC分类号： A62D3/02 , B09C1/10 , C02F3/34 , C12N9/0069 , C12P1/04 , A62D2101/22
摘要： A process for degrading volatile organic contaminants such as trichloroethylene. and remediating volatile organic contaminant contaminated media using trichloroethylene induced toluene monooxygenase activity in Pseudomonas mendocina KR-1 is described.
摘要翻译： 降解挥发性有机污染物如三氯乙烯的方法。 并描述了在假单胞菌KR-1中使用三氯乙烯诱导的甲苯单加氧酶活性来修复挥发性有机污染物污染介质。
-
公开(公告)号：US5164399A
公开(公告)日：1992-11-17
申请号：US793765
申请日：1991-11-18
IPC分类号： C07D498/22
CPC分类号： C07D498/22
摘要： A compound of the structure ##STR1## wherein Z is ##STR2## and R.sup.1 is hydrogen, alkyl, or arylalkyl, provided that when R.sup.2 is present, R.sup.1 is absent;R.sup.2 is hydrogen, alkyl, or arylalkyl, provided that when R.sup.1 is present, R.sup.2 is absent;the dotted lines in the pyrazole ring represent double bonds between the 31- and 32-positions and between the 33- and 53-positions when R.sup.1 is present and double bonds between the 31- and 52-positions and between the 32- and 33-positions when R.sup.2 is present;or a pharmaceutically acceptable salt thereof which by virtue of its immunosuppressive activity is useful in treating transplantation rejection, host vs. graft disease, autoimmune diseases, and diseases of inflammation, by virtue of its antifungal activity is useful in treating fungal infections; and by virtue of its antitumor activity is useful in treating tumors. Intermediates possessing a 31,33-.beta.-dicarbonyl moiety that are useful for the same purposes are also described.
摘要翻译： 结构
的化合物，其中Z为 ，R 1为氢，烷基或芳烷基，条件是当存在R 2时，R 1不存在; R2是氢，烷基或芳基烷基，条件是当R 1存在时，R 2不存在; 吡唑环中的虚线代表31位和32位之间的双键，当R1存在时，33位和53位之间的双键，31位和52位之间以及32位和33位之间的双键， R2存在时的位置; 或其药学上可接受的盐，由于其免疫抑制活性可用于治疗移植排斥反应，宿主与移植物疾病，自身免疫疾病和炎症疾病，由于其抗真菌活性可用于治疗真菌感染; 并且由于其抗肿瘤活性可用于治疗肿瘤。 还描述了具有用于相同目的的31,33-β-二羰基部分的中间体。 -
公开(公告)号：US5120842A
公开(公告)日：1992-06-09
申请号：US678380
申请日：1991-04-01
CPC分类号： C07F7/1856
摘要： A compound of the structure ##STR1## wherein R.sup.1 is --SiR.sup.3 R.sup.4 R.sup.5 ;R.sup.2 is hydrogen or --SiR.sup.3 R.sup.4 R.sup.5 ; andR.sup.3, R.sup.4, and R.sup.5 are each, independently, alkyl, alkenyl, aralkyl, triphenylmethyl, or phenyl which by virtue of its immunosuppressive activity is useful in treating transplantation rejection, host vs. graft disease, autoimmune diseases and diseases of inflammation; by virtue of its antitumor activity is useful in treating solid tumors; and by virtue of its antifungal activity is useful in treating fungal infections. This invention also provides a method of using rapamycin 42-[O-[(1,1-dimethylethyl)-dimethylsilyl] ether for the preparation of 31-substituted rapamycin derivatives.
摘要翻译： 结构
的化合物，其中R 1是-SiR 3 R 4 R 5; R2是氢或-SiR3R4R5; 并且R3，R4和R5各自独立地为烷基，烯基，芳烷基，三苯基甲基或苯基，由于其免疫抑制活性可用于治疗移植排斥反应，宿主与移植物疾病，自身免疫疾病和炎症疾病; 由于其抗肿瘤活性可用于治疗实体瘤; 并且由于其抗真菌活性可用于治疗真菌感染。 本发明还提供了使用雷帕霉素42- [O - [（1,1-二甲基乙基） - 二甲基甲硅烷基]醚来制备31-取代的雷帕霉素衍生物的方法。 -
公开(公告)号：US07241791B2
公开(公告)日：2007-07-10
申请号：US10670646
申请日：2003-09-24
IPC分类号： A61K31/416 , C07D231/56
CPC分类号： C07D231/56 , C07D409/04
摘要： This invention provides compound of formulae I or II having the structure wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 are as defined in the specification or a pharmaceutically acceptable salt thereof which are useful for the treatment of the inflammatory component of diseases and are particularly useful in treating atherosclerosis, myocardial infarction, congestive heart failure, inflammatory bowel disease, arthritis, type II diabetes, and autoimmune diseases such as multiple sclerosis and rheumatiod arthritis.
摘要翻译： 本发明提供具有以下结构的式I或II的化合物，其中R 1，R 2，R 3，R 4， R 5，R 6，R 7，R 8，R 9， SUB＆gt;和R 10＆gt;如说明书中所定义或其药学上可接受的盐，其可用于治疗疾病的炎性成分，并且特别可用于治疗动脉粥样硬化，心肌梗塞，充血性心脏 失败，炎症性肠病，关节炎，II型糖尿病和自身免疫疾病如多发性硬化和风湿性关节炎。
-
7.发明授权Substituted 1-aryl-3-heteroaryl-thioureas and substituted 1-aryl-3-heteroaryl-isothioureas as antiatherosclerotic agents 失效新型取代的1-芳基-3-杂芳基硫脲和取代的1-芳基-3-杂芳基 - 异硫脲作为抗动脉粥样硬化剂公开(公告)号：US06686476B2
公开(公告)日：2004-02-03
申请号：US10212888
申请日：2002-08-06
IPC分类号： C07D27728
CPC分类号： C07D275/03 , A61K31/415 , C07D231/40 , C07D263/48 , C07D277/48 , C07D277/82 , C07D277/84 , C07D285/135
摘要： Antiatherosclerotic agents are provided which are represented by Formulas I or II: wherein R is wherein R9, R10, R11, R12, R13, and R14 are each, independently, hydrogen or a lower alkyl of 1-6 carbon atoms; R6, and R7 are each, independently, hydrogen, lower alkyl of 1-6 carbon atoms, or CH2COOR8, where R8 is a lower alkyl of 1-6 carbon atoms; and X is O or S; R1 is hydrogen or a lower alkyl of 1-6 carbon atoms; R2, R3, and R4 are each, independently, hydrogen or halogen; and R5 is a lower alkyl of 1-6 carbon atoms; or a pharmaceutically acceptable salt thereof.
摘要翻译： 提供由式I或II表示的抗动脉粥样硬化剂：其中R在其中R 9，R 10，R 11，R 12，R 13和R 14各自独立地为氢或1-6个碳原子的低级烷基; R 6和R 7各自为 独立地是氢，1-6个碳原子的低级烷基或CH2COOR8，其中R8是1-6个碳原子的低级烷基; 且X为O或S; R 1为氢或1-6个碳原子的低级烷基; R 2，R 3和R 4各自独立地为氢或卤素; 和R 5是1-6个碳原子的低级烷基;或其药学上可接受的盐。
-
8.发明授权Rapamycin 42-sulfonates and 42-(N-Carboalkoxy)Sulfamates Useful as Immunosuppressive Agents 失效雷帕霉素42-磺酸盐和42-（N-羧基烷氧基）磺酸盐可用作免疫抑制剂
公开(公告)号：US5260299A
公开(公告)日：1993-11-09
申请号：US917555
申请日：1992-07-21
IPC分类号： C07D498/18 , A61K31/395
CPC分类号： C07D498/18
摘要： A derivative of rapamycin of general formula (I) ##STR1## where R.sup.1 is alkyl, alkenyl, or alkynyl containing 1 to 6 carbon atoms; or an aromatic moiety selected from the group consisting of phenyl and naphthyl or a heterocyclic moiety selected from the group consisting of thiophenyl and quinolinyl or NHCO.sub.2 R.sup.2 wherein R.sup.2 is lower alkyl containing 1 to 6 carbon atoms or a pharmaceutically acceptable salt thereof, which by virtue of its immunosuppressive activity is useful in treating transplantation rejection, host versus graft disease, autoimmune diseases, and diseases of inflammation.
摘要翻译： 通式（I）的雷帕霉素的衍生物其中R 1是含有1至6个碳原子的烷基，烯基或炔基; 或选自苯基和萘基的芳族部分或选自噻吩基和喹啉基或NHCO 2 R 2的杂环部分，其中R 2是含有1至6个碳原子的低级烷基或其药学上可接受的盐，其由于 其免疫抑制活性可用于治疗移植排斥反应，宿主与移植物疾病，自身免疫疾病和炎症疾病。
-
9.发明授权Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents 失效雷帕霉素42-磺酸盐和42-（N-烷氧羰基）氨基磺酸盐可用作免疫抑制剂
公开(公告)号：US5177203A
公开(公告)日：1993-01-05
申请号：US846637
申请日：1992-03-05
IPC分类号： C07D498/18
CPC分类号： C07D498/18
摘要： A derivative of rapamycin of general formula (I) ##STR1## where R.sup.1 is alkyl, alkenyl, or alkynyl containing 1 to 6 carbon atoms; or an aromatic moiety selected from the group consisting of phenyl and naphthyl or a heterocyclic moiety selected from the group consisting of thiophenyl and quinolinyl or NHCO.sub.2 R.sup.2 wherein R.sup.2 is lower alkyl containing 1 to 6 carbon atoms or a pharmaceutically acceptable salt thereof, which by virtue of its immunosuppressive activity is useful in treating transplantation rejection, host versus graft disease, autoimmune diseases, and diseases of inflammation.
摘要翻译： 通式（I）的雷帕霉素的衍生物其中R 1是含有1至6个碳原子的烷基，烯基或炔基; 或选自苯基和萘基的芳族部分或选自噻吩基和喹啉基或NHCO 2 R 2的杂环部分，其中R 2是含有1至6个碳原子的低级烷基或其药学上可接受的盐，其由于 其免疫抑制活性可用于治疗移植排斥反应，宿主与移植物疾病，自身免疫疾病和炎症疾病。
-
10.发明授权Substituted tetrahydro-1,3,5-triazin-2[1H]-thiones as anti-atherosclerotic agents 失效取代的四氢-1,3,5-三嗪-2 [1H] - 噻二唑作为抗动脉粥样硬化剂
公开(公告)号：US6160114A
公开(公告)日：2000-12-12
申请号：US960832
申请日：1997-10-30
IPC分类号： A61P3/06 , A61P9/10 , C07D251/08 , C07D239/40
CPC分类号： C07D251/08
摘要： This invention provides compounds of formula 1 having the structure ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, and R.sup.5 are each independently, hydrogen, halogen, alkyl, cycloalkyl, alkenyl, alkynyl, phenylalkyl, alkoxy, aryloxy, fluoroalkoxy, trifluoromethyl, alkylthio, alkylsulfony, --SCF.sub.3, nitro, alkylamino, or dialkylamino;R.sup.6 is hydrogen, alkyl, cycloalkyl, or arylalkyl; andR.sup.7 is alkyl, cycloalkyl, or arylalkylor a pharmaceutically acceptable salt thereof which are useful as antiatherosclerotic agents.
摘要翻译： 本发明提供具有其中R 1，R 2，R 3，R 4和R 5各自独立地为氢，卤素，烷基，环烷基，烯基，炔基，苯基烷基，烷氧基，芳氧基，氟烷氧基，三氟甲基，烷硫基，烷基磺酰基 ，-SCF 3，硝基，烷基氨基或二烷基氨基; R6是氢，烷基，环烷基或芳基烷基; 并且R 7是可用作抗动脉粥样硬化剂的烷基，环烷基或芳烷基或其药学上可接受的盐。
-
-
-
-
-
-
-
-
-
搜索结果
30 条记录 (耗时 0.029 秒)
